APPLICATION
ANDA090899
TYPE
ANDA
ORIGINAL APPROVAL
2011-06-01
LATEST ACTION
2023-03-30
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Discontinued
Products
VENLAFAXINE HYDROCHLORIDEDiscontinued
VENLAFAXINE HYDROCHLORIDE EQ 150MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
VENLAFAXINE HYDROCHLORIDEDiscontinued
VENLAFAXINE HYDROCHLORIDE EQ 37.5MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
VENLAFAXINE HYDROCHLORIDEDiscontinued
VENLAFAXINE HYDROCHLORIDE EQ 75MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
Approval history
2023-03-30Labeling · Supplement 24 · standardAP
2023-03-30Labeling · Supplement 22 · standardAP
2023-03-30Labeling · Supplement 19 · standardAP
2023-03-30Labeling · Supplement 17 · standardAP
2023-03-30Labeling · Supplement 23 · standardAP
2023-03-30Labeling · Supplement 21 · standardAP
2015-09-24Labeling · Supplement 15 · standardAP
2014-12-05Labeling · Supplement 13 · standardAP
2014-01-10Labeling · Supplement 8 · standardAP
2014-01-10Labeling · Supplement 6 · standardAP
2014-01-10Labeling · Supplement 11 · standardAP
2012-10-02Labeling · Supplement 4 · standardAP
2011-06-01OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.